• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纳米医学驱动的肿瘤葡萄糖代谢重编程以增强癌症免疫治疗

Nanomedicine-driven tumor glucose metabolic reprogramming for enhanced cancer immunotherapy.

作者信息

Jiang Chenwei, Tang Minglu, Su Yun, Xie Junjie, Shang Qi, Guo Mingmei, An Xiaoran, Lin Longfei, Wang Ruibin, Huang Qian, Zhang Guangji, Li Hui, Wang Feihu

机构信息

School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.

Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.

出版信息

Acta Pharm Sin B. 2025 Jun;15(6):2845-2866. doi: 10.1016/j.apsb.2025.04.002. Epub 2025 Apr 4.

DOI:10.1016/j.apsb.2025.04.002
PMID:40654336
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12254754/
Abstract

Tumors exhibit abnormal glucose metabolism, consuming excessive glucose and excreting lactate, which constructs a tumor microenvironment that facilitates cancer progression and disrupts immunotherapeutic efficacy. Currently, tumor glucose metabolic dysregulation to reshape the immunosuppressive microenvironment and enhance immunotherapy efficacy is emerging as an innovative therapeutic strategy. However, glucose metabolism modulators lack specificity and still face significant challenges in overcoming tumor delivery barriers, microenvironmental complexity, and metabolic heterogeneity, resulting in poor clinical benefit. Nanomedicines, with their ability to selectively target tumors or immune cells, respond to the tumor microenvironment, co-deliver multiple drugs, and facilitate combinatorial therapies, hold significant promise for enhancing immunotherapy through tumor glucose metabolic reprogramming. This review explores the complex interactions between tumor glucose metabolism-specifically metabolite transport, glycolysis processes, and lactate-and the immune microenvironment. We summarize how nanomedicine-mediated reprogramming of tumor glucose metabolism can enhance immunotherapy efficacy and outline the prospects and challenges in this field.

摘要

肿瘤表现出异常的葡萄糖代谢,消耗过量葡萄糖并分泌乳酸,这构建了一个促进癌症进展并破坏免疫治疗疗效的肿瘤微环境。目前,通过调节肿瘤葡萄糖代谢来重塑免疫抑制微环境并提高免疫治疗疗效正成为一种创新的治疗策略。然而,葡萄糖代谢调节剂缺乏特异性,在克服肿瘤递送障碍、微环境复杂性和代谢异质性方面仍面临重大挑战,导致临床获益不佳。纳米药物能够选择性地靶向肿瘤或免疫细胞,对肿瘤微环境做出反应,共同递送多种药物并促进联合治疗,在通过肿瘤葡萄糖代谢重编程增强免疫治疗方面具有巨大潜力。本文综述探讨了肿瘤葡萄糖代谢(特别是代谢物转运、糖酵解过程和乳酸)与免疫微环境之间的复杂相互作用。我们总结了纳米药物介导的肿瘤葡萄糖代谢重编程如何提高免疫治疗疗效,并概述了该领域的前景和挑战。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/12254754/264b03cbf30b/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/12254754/7cec1f2a90b9/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/12254754/0299cba8d22a/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/12254754/9d791a820884/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/12254754/b7a5bbe35d0e/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/12254754/4f6232dbd788/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/12254754/899f0e3ce27e/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/12254754/14e270f9a7b8/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/12254754/030141d81501/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/12254754/d52e08a4f0ff/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/12254754/264b03cbf30b/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/12254754/7cec1f2a90b9/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/12254754/0299cba8d22a/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/12254754/9d791a820884/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/12254754/b7a5bbe35d0e/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/12254754/4f6232dbd788/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/12254754/899f0e3ce27e/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/12254754/14e270f9a7b8/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/12254754/030141d81501/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/12254754/d52e08a4f0ff/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3711/12254754/264b03cbf30b/gr9.jpg

相似文献

1
Nanomedicine-driven tumor glucose metabolic reprogramming for enhanced cancer immunotherapy.纳米医学驱动的肿瘤葡萄糖代谢重编程以增强癌症免疫治疗
Acta Pharm Sin B. 2025 Jun;15(6):2845-2866. doi: 10.1016/j.apsb.2025.04.002. Epub 2025 Apr 4.
2
Liensinine reshapes the immune microenvironment and enhances immunotherapy by reprogramming metabolism through the AMPK-HIF-1α axis in hepatocellular carcinoma.莲心碱通过激活腺苷酸活化蛋白激酶-低氧诱导因子-1α轴重编程代谢,重塑免疫微环境并增强肝细胞癌的免疫治疗效果。
J Exp Clin Cancer Res. 2025 Jul 15;44(1):208. doi: 10.1186/s13046-025-03477-6.
3
Oncolytic reovirus enhances the effect of CEA immunotherapy when combined with PD1-PDL1 inhibitor in a colorectal cancer model.在结直肠癌模型中,溶瘤呼肠孤病毒与PD1-PDL1抑制剂联合使用时可增强CEA免疫疗法的效果。
Immunotherapy. 2025 Apr;17(6):425-435. doi: 10.1080/1750743X.2025.2501926. Epub 2025 May 12.
4
Cancer-associated fibroblast-derived extracellular vesicles loaded with GLUT1 inhibitor synergize anti-PD-L1 to suppress tumor growth via degrading matrix stiffness and remodeling tumor microenvironment.负载GLUT1抑制剂的癌症相关成纤维细胞衍生的细胞外囊泡与抗PD-L1协同作用,通过降解基质硬度和重塑肿瘤微环境来抑制肿瘤生长。
J Control Release. 2025 Jul 1:113998. doi: 10.1016/j.jconrel.2025.113998.
5
TIGIT expression dictates the immunosuppressive reprogramming of myeloid cells in glioblastoma.TIGIT表达决定了胶质母细胞瘤中髓系细胞的免疫抑制重编程。
bioRxiv. 2025 May 2:2025.04.24.648993. doi: 10.1101/2025.04.24.648993.
6
Glioma promotes macrophage immunosuppressive phenotype through ANXA1 in a methionine metabolism-dependent manner.胶质瘤通过膜联蛋白A1以甲硫氨酸代谢依赖的方式促进巨噬细胞免疫抑制表型。
Discov Oncol. 2025 Jul 6;16(1):1269. doi: 10.1007/s12672-025-03112-y.
7
Short-Term Memory Impairment短期记忆障碍
8
An update on cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer.三阴性乳腺癌中与化疗耐药相关的癌症干细胞存活途径的最新进展。
Future Oncol. 2025 Mar;21(6):715-735. doi: 10.1080/14796694.2025.2461443. Epub 2025 Feb 12.
9
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
10
The Overlapping Biology of Sepsis and Cancer and Therapeutic Implications.脓毒症与癌症的重叠生物学特性及其治疗意义
Biomedicines. 2025 May 23;13(6):1280. doi: 10.3390/biomedicines13061280.

引用本文的文献

1
Nanotechnology and natural killer cell immunotherapy: synergistic approaches for precise immune system adjustment and targeted cancer treatment in gastrointestinal tumors.纳米技术与自然杀伤细胞免疫疗法:胃肠道肿瘤中精确调节免疫系统和靶向癌症治疗的协同方法。
Front Med (Lausanne). 2025 Aug 21;12:1647737. doi: 10.3389/fmed.2025.1647737. eCollection 2025.
2
Spatiotemporal Heterogeneity of Tumor Glucose Metabolism Reprogramming: From Single-Cell Mechanisms to Precision Interventions.肿瘤葡萄糖代谢重编程的时空异质性:从单细胞机制到精准干预
Int J Mol Sci. 2025 Jul 18;26(14):6901. doi: 10.3390/ijms26146901.

本文引用的文献

1
Insulin-like growth factor 2 drives fibroblast-mediated tumor immunoevasion and confers resistance to immunotherapy.胰岛素样生长因子 2 驱动成纤维细胞介导的肿瘤免疫逃逸,并赋予对免疫治疗的抗性。
J Clin Invest. 2024 Nov 15;134(22):e183366. doi: 10.1172/JCI183366.
2
Harnessing glucose metabolism with nanomedicine for cancer treatment.利用纳米医学来调节葡萄糖代谢以治疗癌症。
Theranostics. 2024 Oct 17;14(17):6831-6882. doi: 10.7150/thno.100036. eCollection 2024.
3
H3K9 lactylation in malignant cells facilitates CD8 T cell dysfunction and poor immunotherapy response.
恶性细胞中的H3K9乳酸化促进CD8 T细胞功能障碍和免疫治疗反应不佳。
Cell Rep. 2024 Nov 26;43(11):114957. doi: 10.1016/j.celrep.2024.114957. Epub 2024 Oct 30.
4
The changing landscape of cancer cell therapies: clinical trials and real-world data.癌细胞疗法的不断变化态势:临床试验与真实世界数据
Nat Rev Drug Discov. 2024 Oct;23(10):736-737. doi: 10.1038/d41573-024-00094-4.
5
PKM2 functions as a histidine kinase to phosphorylate PGAM1 and increase glycolysis shunts in cancer.PKM2 作为组氨酸激酶发挥作用,使 PGAM1 磷酸化并增加癌症中的糖酵解分流。
EMBO J. 2024 Jun;43(12):2368-2396. doi: 10.1038/s44318-024-00110-8. Epub 2024 May 15.
6
Nanoparticles for inducing Gaucher disease-like damage in cancer cells.用于诱导癌细胞发生 Gaucher 病样损伤的纳米颗粒。
Nat Nanotechnol. 2024 Aug;19(8):1203-1215. doi: 10.1038/s41565-024-01668-4. Epub 2024 May 13.
7
A lactate-SREBP2 signaling axis drives tolerogenic dendritic cell maturation and promotes cancer progression.乳酸-SREBP2 信号轴驱动耐受原性树突状细胞成熟并促进癌症进展。
Sci Immunol. 2024 May 10;9(95):eadi4191. doi: 10.1126/sciimmunol.adi4191.
8
A Multifunctional Nanoreactor-Induced Dual Inhibition of HSP70 Strategy for Enhancing Mild Photothermal/Chemodynamic Synergistic Tumor Therapy.多功能纳米反应器诱导的 HSP70 双重抑制增强温和光热/化学动力学协同肿瘤治疗策略。
Adv Healthc Mater. 2024 Sep;13(23):e2400819. doi: 10.1002/adhm.202400819. Epub 2024 May 17.
9
Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma.葡萄糖驱动的组蛋白乳糖化促进了脑胶质母细胞瘤中单核细胞来源的巨噬细胞的免疫抑制活性。
Immunity. 2024 May 14;57(5):1105-1123.e8. doi: 10.1016/j.immuni.2024.04.006. Epub 2024 May 3.
10
Dual-Targeted Novel Temozolomide Nanocapsules Encapsulating siPKM2 Inhibit Aerobic Glycolysis to Sensitize Glioblastoma to Chemotherapy.包裹siPKM2的双靶点新型替莫唑胺纳米胶囊抑制有氧糖酵解,使胶质母细胞瘤对化疗敏感。
Adv Mater. 2024 Jul;36(29):e2400502. doi: 10.1002/adma.202400502. Epub 2024 May 13.